Zobrazeno 41 - 50
of 55
pro vyhledávání: '"35"'
Autor:
Mogens Herman Hansen, Per Dombernowsky, B. M. B. Schousboe, Jørn Herrstedt, T.C. Sigsgaard, J. Handberg
Publikováno v:
Journal of Clinical Oncology. 15:1690-1696
PURPOSE To investigate the antiemetic effect and tolerability of the 5-hydroxytryptamine3(5-HT3) antagonist ondansetron plus the dopamine D2 antagonist metopimazine versus ondansetron alone in patients receiving platinum-based chemotherapy. PATIENTS
Autor:
Philippe Moreau, N Straetmans, I Tabah, Philippe Solal-Celigny, Corinne Haioun, Nicole Brousse, Pauline Brice, Eric Lepage, H. Tilly, Y. Bastion
Publikováno v:
Journal of Clinical Oncology. 15:1110-1117
PURPOSE To evaluate prospectively in patients with follicular lymphoma and a low tumor burden three therapeutic options: delay of any treatment until clinically meaningful progression, immediate treatment with an oral alkylating agent, or treatment w
Autor:
Rosemarie Mick, Brian L. Samuels, Harvey M. Golomb, L. C. Drinkard, Alfred Guaspari, Gregory A. Masters, Ai-ly Hsieh, Philip C. Hoffman, Everett E. Vokes
Publikováno v:
Journal of Clinical Oncology. 15:884-892
PURPOSE We designed a phase I dose-escalation study of vinorelbine on a novel (daily-times-three) schedule with ifosfamide with granulocyte colony-stimulating factor (G-CSF) support to define the dose-limiting toxicity (DLT) and maximum-tolerated dos
Autor:
R. Rodriguez, M A Cuevas, C. L. Sabatini, J. A. Lacava, Bernardo Amadeo Leone, L A Acuña, M Machiavelli, Maria Ester Dominguez, M. A. Salvadori, E. H. Ortiz, Carlos Teodoro Vallejo, J M Acuña, M. J. Langhi, M R Barbieri, S. Amato, J E Perez, A Romero
Publikováno v:
Journal of Clinical Oncology. 14:2993-2999
PURPOSE To evaluate the efficacy and toxicity of the combination of ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy in metastatic breast cancer (MBC). PATIENTS AND METHODS Between August 1993 and August 1995, 45 patients with untrea
Autor:
M. R. Cooper, Karen H. Antman, Mark R. Green, Nicholas J. Vogelzang, James E. Herndon, Joseph M. Corson, L B Weissman
Publikováno v:
Journal of Clinical Oncology. 12:1436-1442
PURPOSE Folic acid antagonists are reported to have activity against mesothelioma. The Cancer and Leukemia Group B (CALGB) undertook this phase II study of the new antifolate, trimetrexate (TMTX), to evaluate its response rate and toxicity in chemoth
Autor:
Barry E. Storer, Chris Feierabend, Rhoda Z. Arzoomanian, Joan H. Schiller, David R. Spriggs, Dona Alberti, Kendra D. Tutsch
Publikováno v:
Journal of Clinical Oncology. 12:241-248
PURPOSE We conducted a phase I trial of a 3-hour infusion of Taxol (paclitaxel; Bristol-Myers Squibb Co, Princeton, NJ) to identify the maximum-tolerated dose of Taxol as a 3-hour infusion with and without granulocyte colony-stimulating factor (G-CSF
Autor:
G. De Palo, Tiziana Campa, Andrea Magni, Mario Clerici, Aurora Costa, Umberto Veronesi, G. Mascotti, M G Di Mauro, Franca Formelli, Daniele Moglia
Publikováno v:
Journal of Clinical Oncology. 11:2036-2042
PURPOSE Monitoring of fenretinide (4HPR) levels, kinetics, and effects on retinal was performed in patients who participated in a phase I trial and who continued to be treated for 5 years as phase III trial patients. Accumulation of 4HPR in the breas
Autor:
Peter G. Rose, Gertrude Peterson, Nancy Fusco, Jerome L. Belinson, Maurie Markman, Alexander W. Kennedy, Ira R. Horowitz, Kenneth Webster, Elizabeth Jones, Lisa Fluellen, William P. McGuire, Barb Kulp
Publikováno v:
Journal of Clinical Oncology. 16:1849-1851
PURPOSE To test the hypothesis that prolonged infusion of paclitaxel (96 hours) might overcome resistance to shorter infusion schedules (3 or 24 hours) in ovarian cancer. PATIENTS AND METHODS A total of 30 patients with advanced ovarian cancer (24 pa
Autor:
Nikolous J. Fox, Bonnie S. Glisson, Roman Perez-Soler, Michael B. Ross, William K. Murphy, Dong M. Shin, David A. Nyberg, Waun Ki Hong, Frank V. Fossella, Katherine M.W. Pisters, Jin S. Lee, Jonathan M. Kurie
Publikováno v:
Journal of Clinical Oncology. 17:2309-2309
PURPOSE: The combination of cisplatin, etoposide, and paclitaxel was studied in patients with extensive small-cell lung cancer in a phase I component followed by a phase II trial to determine the maximum-tolerated dose (MTD), characterize toxicity, a
Autor:
B C Wen, F R Dick, John D. Kemp, J E Radford, C P Burns, R D Gingrich, M P Jones, D B McFadden, R. W. Edwards
Publikováno v:
Journal of Clinical Oncology. 7:58-66
Fifty-nine consecutive previously untreated adult patients with acute lymphoblastic leukemia (ALL) were entered onto a prospective single-arm trial of doxorubicin, vincristine, prednisone, and asparaginase (HOP-L) induction therapy followed by CNS pr